Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

被引：0
|
作者：
Kelly, Karen
Mazieres, Julien
Leighl, Natasha B.
Barlesi, Fabrice
Zalcman, Gerard
Gordon, Michael S.
Reckamp, Karen L.
Gandara, David R.
Gomez-Roca, Carlos Alberto
Bennouna, Jaafar
Cho, Byoung Chul
Park, Keunchil
Infante, Jeffrey R.
Richards, Donald A.
Wu, Yuehui
Schramek, Daniel J.
Cox, Donna S.
Gardner, Olivia S.
Peddareddigari, Vijay Gopal Reddy
Blumenschein, George R.
机构：
[1] UC Davis Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA
[2] Hop Larrey CHU Toulouse, Toulouse, France
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Aix Marseille Univ, Hop Nord, Assistance Publ Hop Marseille, Marseille, France
[5] Caen Univ Hosp, Caen, France
[6] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[7] City Hope Comprehens Canc Ctr, Duarte, CA USA
[8] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[9] Inst Claudius Regaud, Toulouse, France
[10] Inst Cancerol Ouest, Nantes, France
[11] Yonsei Univ, Coll Med, Seoul, South Korea
[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[13] Sarah Cannon Res Inst, Nashville, TN USA
[14] Tennessee Oncol, Nashville, TN USA
[15] Texas Oncol, Houston, TX USA
[16] GlaxoSmithKline, Collegeville, PA USA
[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    Gandara, David R.
    Hiret, Sandrine
    Blumenschein, George R.
    Barlesi, Fabrice
    Delord, Jean-Pierre
    Madelaine, Jeannick
    Infante, Jeffrey R.
    Reckamp, Karen L.
    Lara, Primo
    Audebert, Christine
    Cho, Byoung Chul
    Park, Keunchil
    Braiteh, Fadi S.
    Jotte, Robert M.
    Wu, Yuehui
    Schramek, Daniel J.
    Piepszak, Alexandra M.
    Gardner, Olivia S.
    Peddareddigari, Vijay Gopal Reddy
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH PEMETREXED IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS
    Mazieres, Julien
    Gandara, David R.
    Leighl, Natasha B.
    Wheler, Jennifer J.
    Barlesi, Fabrice
    Zalcman, Gerard
    Kelly, Karen
    Reckamp, Karen L.
    Gordon, Michael S.
    Hiret, Sandrine
    Shepherd, Frances A.
    Janku, Filip
    Cho, Byoung Chul
    Park, Keunchil
    Infante, Jeffrey R.
    Richards, Donald A.
    Wu, Yuehui
    Schramek, Daniel J.
    Cox, Donna S.
    Piepszak, Alexandra M.
    Liu, Yuan
    Gardner, Olivia S.
    Peddareddigari, Vijay G. R.
    Blumenschein, George R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S369 - S370
  • [3] ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH DOCETAXEL IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS
    Bennouna, Jaafar
    Leighl, Natasha B.
    Kelly, Karen
    Blumenschein, George R.
    Zalcman, Gerard
    Audebert, Christine
    Gomez-Roca, Carlos
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Lara, Primo
    Shepherd, Frances A.
    Janku, Filip
    Cho, Byoung Chul
    Park, Keunchil
    Braiteh, Fadi S.
    Jotte, Robert M.
    Wu, Yuehui
    Schramek, Daniel J.
    Cox, Donna S.
    Piepszak, Alexandra M.
    Liu, Yuan
    Gardner, Olivia S.
    Peddareddigari, Vijay G. R.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S370 - S371
  • [4] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
    Blumenschein, G. R., Jr.
    Smit, E. F.
    Planchard, D.
    Kim, D. -W.
    Cadranel, J.
    De Pas, T.
    Dunphy, F.
    Udud, K.
    Ahn, M. -J.
    Hanna, N. H.
    Kim, J. -H.
    Mazieres, J.
    Kim, S. -W.
    Baas, P.
    Rappold, E.
    Redhu, S.
    Puski, A.
    Wu, F. S.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 894 - 901
  • [5] A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
    Tolcher, A. W.
    Bendell, J. C.
    Papadopoulos, K. P.
    Burris, H. A., III
    Patnaik, A.
    Jones, S. F.
    Rasco, D.
    Cox, D. S.
    Durante, M.
    Bellew, K. M.
    Park, J.
    Le, N. T.
    Infante, J. R.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 58 - 64
  • [6] A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.
    Becerra, Carlos
    Infante, Jeffrey R.
    Garbo, Lawrence E.
    Gordon, Michael S.
    Smith, David A.
    Braiteh, Fadi S.
    Gandara, David R.
    Jotte, Robert M.
    Reckamp, Karen L.
    Janku, Filip
    Burris, Howard A.
    Bellew, Kevin M.
    Gardner, Olivia S.
    Liu, Li
    Cox, Donna S.
    Peddareddigari, Vijay Gopal Reddy
    Blumenschein, George R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
    Anthony W. Tolcher
    Razelle Kurzrock
    Vincente Valero
    Rene Gonzalez
    Rebecca S. Heist
    Antoinette R. Tan
    Julie Means-Powell
    Theresa L. Werner
    Carlos Becerra
    Chenxi Wang
    Cathrine Leonowens
    Shanker Kalyana-Sundaram
    Joseph F. Kleha
    Jennifer Gauvin
    Anthony M. D’Amelio
    Catherine Ellis
    Nageatte Ibrahim
    Li Yan
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 673 - 683
  • [8] Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
    Tolcher, Anthony W.
    Kurzrock, Razelle
    Valero, Vincente
    Gonzalez, Rene
    Heist, Rebecca S.
    Tan, Antoinette R.
    Means-Powell, Julie
    Werner, Theresa L.
    Becerra, Carlos
    Wang, Chenxi
    Leonowens, Cathrine
    Kalyana-Sundaram, Shanker
    Kleha, Joseph F.
    Gauvin, Jennifer
    D'Amelio, Anthony M.
    Ellis, Catherine
    Ibrahim, Nageatte
    Yan, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 673 - 683
  • [9] A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
    Koh, R. Keng
    Califano, R.
    Dean, E.
    Kosmin, J.
    Ataman, O.
    Jackson, A.
    Blackhall, F. H.
    Faivre-Finn, C.
    LUNG CANCER, 2010, 67 : S33 - S34
  • [10] A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer
    Riess, J.
    Schalper, K.
    Kelly, K.
    Shimoda, M.
    Luxardi, G.
    Merleev, A.
    Monjazeb, A.
    Danenberg, K.
    Maverakis, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S345 - S345
12345